Concise Review: Pluripotent Stem Cell-Derived Cardiac Cells, A Promising Cell Source for Therapy of Heart Failure: Where Do We Stand?

被引:23
|
作者
Gouadon, Elodie [1 ]
Moore-Morris, Thomas [2 ]
Smit, Nicoline W. [3 ]
Chatenoud, Lucienne [4 ]
Coronel, Ruben [3 ]
Harding, Sian E. [5 ]
Jourdon, Philippe [1 ]
Lambert, Virginie [1 ]
Rucker-Martin, Catherine [1 ]
Puceat, Michel [2 ]
机构
[1] IPSIT Ctr Chirurg Marie Lanelongue, LabEx LERMIT, INSERM UMR S999, Paris, France
[2] Univ Aix Marseille, INSERM GMGF, UMRS 910, Marseille, France
[3] Univ Amsterdam, Acad Med Ctr, Dept Clin & Expt Cardiol, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Paris 05, INSERM U1151, Sorbonne Paris Cite, Paris, France
[5] Univ London Imperial Coll Sci Technol & Med, London, England
关键词
Cellular therapy; Embryonic stem cells; Pluripotent stem cells; Progenitor cells; Tissue regeneration; Cardiac; RIGHT-VENTRICULAR FUNCTION; ACUTE MYOCARDIAL-INFARCTION; IMMUNOSUPPRESSIVE THERAPY; TRANSITION CONTRIBUTES; TOLERANCE INDUCTION; CHRONIC OVERLOAD; OVINE MODEL; CARDIOMYOCYTES; REPAIR; MECHANISMS;
D O I
10.1002/stem.2205
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Heart failure is still a major cause of hospitalization and mortality in developed countries. Many clinical trials have tested the use of multipotent stem cells as a cardiac regenerative medicine. The benefit for the patients of this therapeutic intervention has remained limited. Herein, we review the pluripotent stem cells as a cell source for cardiac regeneration. We more specifically address the various challenges of this cell therapy approach. We question the cell delivery systems, the immune tolerance of allogenic cells, the potential proarrhythmic effects, various drug mediated interventions to facilitate cell grafting and, finally, we describe the pathological conditions that may benefit from such an innovative approach. As members of a transatlantic consortium of excellence of basic science researchers and clinicians, we propose some guidelines to be applied to cell types and modes of delivery in order to translate pluripotent stem cell cardiac derivatives into safe and effective clinical trials.
引用
收藏
页码:34 / 43
页数:10
相关论文
共 50 条
  • [1] Stem cell therapy in heart failure: Where do we stand today?
    Nair, Nandini
    Gongora, Enrique
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2020, 1866 (04):
  • [2] Cell transplantation in heart failure: where do we stand in 2016?
    MacArthur, John W.
    Goldstone, Andrew B.
    Cohen, Jeffrey E.
    Hiesinger, William
    Woo, Y. Joseph
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 50 (03) : 396 - 399
  • [3] Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes
    Park, Misun
    Yoon, Young-sup
    KOREAN CIRCULATION JOURNAL, 2018, 48 (11) : 974 - 988
  • [4] A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine
    Pushp, Pallavi
    Nogueira, Diogo E. S.
    Rodrigues, Carlos A. V.
    Ferreira, Frederico C.
    Cabral, Joaquim M. S.
    Gupta, Mukesh Kumar
    STEM CELL REVIEWS AND REPORTS, 2021, 17 (03) : 748 - 776
  • [5] A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine
    Pallavi Pushp
    Diogo E. S. Nogueira
    Carlos A. V. Rodrigues
    Frederico C. Ferreira
    Joaquim M. S. Cabral
    Mukesh Kumar Gupta
    Stem Cell Reviews and Reports, 2021, 17 : 748 - 776
  • [6] Concise Review: Maturation Phases of Human Pluripotent Stem Cell-Derived Cardiomyocytes
    Robertson, Claire
    Tran, David D.
    George, Steven C.
    STEM CELLS, 2013, 31 (05) : 829 - 837
  • [7] Cardiac Cell Therapy with Pluripotent Stem Cell-Derived Cardiomyocytes: What Has Been Done and What Remains to Do?
    Selvakumar, Dinesh
    Reyes, Leila
    Chong, James J. H.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (05) : 445 - 461
  • [8] Modeling Heart Failure With Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell-Derived Cardiac Organoids
    Haim, Idan Refael
    Gruber, Amit
    Kazma, Noam
    Bashai, Caroline
    Kinsbruner, Hava Lichtig
    Caspi, Oren
    CIRCULATION-HEART FAILURE, 2025, 18 (03)
  • [9] Stem cell therapy for Parkinson's disease: where do we stand?
    Roybon, L
    Christophersen, NS
    Brundin, P
    Li, JY
    CELL AND TISSUE RESEARCH, 2004, 318 (01) : 261 - 273
  • [10] Stem cell therapy for ischemic heart disease: where are we?
    Lapar, Damien J.
    Kron, Irving L.
    Yang, Zequan
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2009, 14 (01) : 79 - 84